Significance Statement {#s1}
======================

Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels responsible for rapid excitatory acetylcholine signaling, which modulate numerous circuits involved in complex behaviors. In addition, nAChRs are the primary targets for the reinforcing effects of nicotine in tobacco products. Proteins associated with nAChRs are critical for receptor trafficking, localization, and function. Identifying the core elements of the nAChR-associated proteome that are conserved across human and mouse brain is essential for understanding how these receptors are regulated, and how their functions and interactions are altered by long-term exposure to nicotine.

Introduction {#s2}
============

Individuals who smoke have significantly higher numbers of high-affinity nicotinic acetylcholine receptors (nAChRs) compared to nonsmokers, as measured in both postmortem brain studies ([@B2]) and SPECT imaging studies with a radiotracer specific for nAChRs containing the β2 subunit (β2\*-nAChRs; [@B45]). This upregulation appears to be due primarily to the nicotine in tobacco, since rodent studies demonstrate that long-term exposure to nicotine alone results in a similar upregulation of β2\*-nAChRs in brain ([@B24]). While this change in receptor number can alter signaling through nAChRs ([@B3]; [@B9]), the effect of nicotine treatment and upregulation on the associated proteome is not known. Identifying the complex associated with upregulated nAChRs would be helpful in understanding both the basic biology of the nAChR system, as well as the consequences of smoking on nAChR-induced intracellular signaling. Comparison of the nAChR-associated proteome in human smokers versus rodents exposed to nicotine is also important to identify molecular changes selective for nicotine alone, rather than the ∼4000 other constituents of tobacco smoke. Further, the identification of the changes in the nAChR-associated proteome as a result of nicotine exposure could provide insights into the mechanisms underlying nAChR upregulation, as well as determining whether nicotine-mediated upregulation alters the downstream signaling of these receptors. Finally, comparison of the human and rodent nAChR-associated proteome at baseline could identify conserved signaling pathways that important for ongoing smoking behavior and other disorders associated with changes in nAChR signaling.

Among disorders associated with smoking, mood disorders (MDs) are of particular interest because of the high comorbidity reported ([@B23]; [@B21]; [@B30]) and because several lines of evidence implicate the dysfunction of the cholinergic system in depressive states (for review, see [@B31]; [@B36]). Animal and human studies suggest that increased ACh activity can induce symptoms of depression, whereas decreased cholinergic activity may be associated with mania ([@B6]; [@B7]). Consistent with challenge studies using a cholinesterase inhibitor to increase nAChR occupancy ([@B8]), imaging studies suggest that brain ACh levels may be higher in individuals with major depressive or bipolar disorder when they are actively depressed ([@B43]; [@B10]). With respect to nAChRs, decreasing the activity of β2\*-nAChRs using molecular genetics, pharmacological antagonism, or partial agonism can alter behavior in tests of antidepressant efficacy ([@B4]; [@B39]; [@B32]). Overall nAChR signaling may be altered in individuals with depressive disorders, suggesting that it could be important to identify any potential differences in the functional regulation of β2\*-nAChRs and protein--protein interactions in patients with affective disorders.

In the current study, we took a dual approach to identify changes in the nAChR-associated proteome with nicotine exposure and to determine whether any changes were also apparent in individuals with a mood disorder. We obtained postmortem tissue from the temporal cortex of human subjects and used tissue cotinine content as a determinant of tobacco use to determine whether there was any difference in the nAChR-associated proteome as a function of receptor number. (Note that we use "tobacco use" rather than "smoker" since it is not possible to discriminate between modes of tobacco use from brain metabolite levels). Among the human subjects, we evaluated cortical tissue from both healthy control subjects and matched individuals with a mood disorder diagnosis to identify any differences in receptor number or response to smoking. In addition, we exposed mice with differing levels of high-affinity nAChRs to nicotine in the long term to identify changes in the associated proteome that do or do not scale with nAChR number to determine which smoking-induced changes in human tissue can be attributed to the nicotine in tobacco. These results are the first to compare human and mouse nAChR-associated proteins, and the findings identify conserved proteins in the β2\*-nAChR interactome and the effects of nicotine exposure that are valid to explore with other models.

Materials and Methods {#s3}
=====================

Human temporal cortex tissue collection {#s3A}
---------------------------------------

Human temporal cortex samples were obtained from the Douglas Brain Bank as frozen tissue sections, ranging from 0.29 to 1.03 g wet weight of tissue. Visual inspection of each section indicated approximately equivalent amounts of gray and white matter per section. All tissue samples were numbered by the supplier, with diagnosis (major depressive, bipolar, mood disorder not otherwise specified, or no mood disorder) and cause of death as the only additional information. Experimental results were not sorted by diagnosis until after results were obtained; experimenters were blind to the groups during data collection.

Mice {#s3B}
----

Wild-type mice and mice carrying genetic deletion of the β2 nAChR subunit ([@B37]) or the α4 nAChR subunit ([@B42]) were used for these studies. The animals used were wild type (β2^+/+^), heterozygous (β2^+/−^), α4/β2 double-heterozygous (α4^+/−^β2^+/−^), and knock-out (β2^−/−^) mice. Mice were bred and maintained in the animal colonies at the University of Colorado and Yale University. Female mice were used for this study because females are more resilient to chronic nicotine administration ([@B11]) and were housed in groups of no more than five same-sex littermates per cage, on a 12 h light/dark cycle with *ad libitum* access to food and water. All protocols involving the use of live animals were approved by and followed the guidelines of the institutional animal care and use committees of the University of Colorado and Yale University.

Surgery and long-term nicotine treatment {#s3C}
----------------------------------------

Mice were fitted with jugular catheters essentially as described previously ([@B25]), with minor modifications. Briefly, mice were anesthetized with an intraperitoneal injection of ketamine/xylazine (100/8 mg/kg) and a small incision (\<1 cm) was made above the right clavicle to access the superficial aspect of the jugular vein. A small catheter (inner diameter, 0.51 mm; outer diameter, 0.94 mm) made of medical-grade silastic tubing and filled with sterile saline solution was inserted into the exposed vein and anchored in position with two surgical silk sutures. The catheter was passed under the skin through a second small (\<1 cm) incision made in the midthoracic region of the skin and was attached to a stainless steel post anchored under the skin with veterinary adhesive. Incisions were cleaned with 0.1% iodine in ethanol and closed with veterinary adhesive. Mice were given an intraperitoneal injection of buprenorphine (0.1 mg/kg) following surgery and were allowed to recover in warm (37^°^C) individual cages. For long-term infusion, mice were housed individually, and the jugular catheter was attached to a 1 ml syringe pump and infused with saline at a rate of 35 μl/h for 48 h. Vehicle control mice received sterile saline, and nicotine-treated animals received 4 mg/kg/h nicotine (free base, neutralized with HCl) for a total of 10 d. On the last day of nicotine treatment, mice were detached from the syringe pump and allowed to clear the nicotine for 2 h. Mice were killed by cervical dislocation, and the brain was rapidly removed and placed on an ice-cold surface for dissection. Each brain was dissected, and the cortex was frozen at −80^°^C until analysis.

\[^125^I\]-Epibatidine binding {#s3D}
------------------------------

Quantification of high-affinity nAChR binding sites in brain tissue was performed essentially as described previously ([@B10]) with minor modifications. Briefly, a small prism of tissue was removed from the large frozen section by dissection on an ice-cold surface with a sterile scalpel. The excised tissue was placed immediately in 0.25 ml ice-cold 0.1× phosphate buffer (PB; 12.8 m[m]{.smallcaps} NaCl, 0.24 m[m]{.smallcaps} KCl, 0.32 m[m]{.smallcaps} CaCl~2~, 0.12 m[m]{.smallcaps} KH~2~PO~4~, 0.12 m[m]{.smallcaps} MgSO~4~.7H~2~O, 2.5 m[m]{.smallcaps} HEPES hemi-Na, pH7.5). Samples were homogenized by hand in a glass/Teflon tissue grinder and diluted to a final volume of 0.5 ml in 0.1× PB. The tissue homogenate was centrifuged at 10,000 x g at 4^°^C for 20 min, and the supernatant was discarded. The tissue pellet was resuspended in 0.5 ml of 0.1× PB and centrifuged for 20 min at 10,000 × *g* at 4^°^C. This wash step was repeated a total of three times in order to ensure the removal of substances that could compete with \[^125^\]I-epibatidine binding (i.e., nicotine, ACh). For ligand binding to particulate fractions, 10 μl aliquots of tissue homogenate were added to wells of 96-well plates containing 200 p[m]{.smallcaps} \[^125^I\]-epibatidine as the final concentration ([@B51]). Nonspecific binding was assessed in the presence of 100 μ[m]{.smallcaps} cytisine. The protein content of each sample was determined using the method of [@B54].

Immunopurification of β2\*-nAChRs {#s3E}
---------------------------------

Purification of β2\*-nAChRs with mAb295-coupled M270 Dynabeads from mouse and human cortical tissue samples was conducted essentially as described previously ([@B27]), with minor modifications. For the mouse cortex samples, dissected cortices (both hemispheres) from two mice were pooled to create one homogenate for immunoprecipitation (IP); human samples were used as is, and the volume of homogenization buffer was adjusted to equal 4 volumes based on the total wet weight of the tissue. Briefly, brain tissue sections were homogenized by hand with 17 strokes in a glass/Teflon tissue grinder with 4 volumes of ice-cold PBS (pH 8.0), and placed on ice. To each tissue homogenate, dithiobis\[succinimidyl propionate\] \[DSP (also called Lamont\'s Reagent); 12 Å linker span; 10 m[m]{.smallcaps} in DMSO\] was added to a final concentration of 1 m[m]{.smallcaps} to stabilize labile interactions prior to detergent extraction. Tissue homogenates were incubated on ice for 45 min with DSP prior to the addition of Tris to a final concentration of 10 m[m]{.smallcaps} to quench the crosslinking reaction. Samples were centrifuged at 10,000 × *g* at 4^°^C for 20 min, and the supernatant was collected and frozen at −20^°^C, and the pellet was washed by resuspension in TBS before being centrifuged again. The washed pellet was resuspended in 2 ml of extraction buffer (EB; in m[m]{.smallcaps}: 121.9 NaCl, 2.68 KCl, 10.14 Na~2~HPO~4~, 1.76 KH~2~PO~4~, 5 EDTA, 5 EGTA, 5 NaF, 0.1 Na~3~VO~4~, 1.0 PMSF, 10 μg/ml each of aprotonin, prepstatin A, leupeptin, 0.and 6% Triton X-100, pH 7.4) and incubated for 30 min with gentle rotation at room temperature. The extract was clarified by centrifugation at 10,000 × *g* at 4^°^C for 20 min, and the supernatant was collected. A 100 μl aliquot of clarified extract was taken at this point to quantify total extracted nAChR content with \[^125^I\]-epibatidine binding, as described below. The remaining extract was added to 5 ml of polystyrene culture tubes containing a volume of mAb295-Dynabeads equivalent to 50% of the input volume and incubated with gentle rotation at 4^°^C overnight. The following morning, sample tubes were placed on a magnetic stand to separate the mAb295 beads, and a 100 μl aliquot of the supernatant was collected to assess nAChR capture efficiency. For the quantification of nAChR immunopurification, 20 μl aliquots of input and post-IP tissue lysate were labeled with 200 p[m]{.smallcaps} \[^125^I\]-epibatidine overnight at 4^°^C, and protein precipitated by 50 μl of 40% w/v polyethylene glycol (PEG) added to each well. PEG-precipitated binding sites were captured on filter membranes as for the particulate binding studies. The depletion of binding sites was used to estimate receptor content of each sample post-elution.

Sample preparation and protein identification by liquid chromatography-tandem mass spectrometry {#s3F}
-----------------------------------------------------------------------------------------------

Dynabeads carrying mAb295-captured nAChRs and bound proteins were washed two times with 1 ml of PBS (137 m[m]{.smallcaps} NaCl, 27 m[m]{.smallcaps} KCl, 100 m[m]{.smallcaps} Na~2~HPO4, 18 m[m]{.smallcaps} KH~2~PO~4~, pH 7.5) containing 0.01% Tween-20, and one time with PBS prior to elution with 0.5 ml of 0.1 [m]{.smallcaps} NH~4~OH and 1 m[m]{.smallcaps} EDTA, pH 10.0. Elution was performed twice, and eluates were pooled prior to lyophilization in a Thermo Savant SPD1010 Speedvac. Eluted proteins were reduced, alkylated, and digested as described previously ([@B27]). Mouse cortex samples were labeled in an eight-plex iTRAQ labeling scheme, and peptide sequencing was performed on an ABSciex 5600 triple- time-of-flight mass spectrometer, with iTRAQ quantitation in ProteinPilot software, as has been described ([@B27]). For the human temporal cortex samples, the eluted protein pellet was redissolved in 30 µl of 8 [m]{.smallcaps} urea/0.4 [m]{.smallcaps} ammonium bicarbonate, pH 8.0. The addition of 3 µl of 45 m[m]{.smallcaps} DTT was followed by vortexing, and samples were then incubated at 37°C for 20 min. Reduced samples were cooled to room temperature and alkylated with 3 µl of 100 m[m]{.smallcaps} iodoacetamide for 20 min in the dark. Water (74 µl) was added to dilute the sample prior to trypsin digestion (10 µl, 0.5 mg/ml) at 37°C overnight. Samples were desalted on a Macrospin cartridge (Nest Group), and eluent was dried in a Speedvac. The pellet was resuspended in 10 µl of 70% formic acid and 40 µl of 50 m[m]{.smallcaps} sodium PB. Equal peptide amounts were aliquoted into glass vials for injection.

Proteomic analysis was performed using a label-free quantification (LFQ) method on an Orbitrap Elite equipped with a Waters Symmetry C18 (180 µm × 20 mm) trap column and a 1.7 µm, 75 µm × 250 mm nanoAcquity ultra high-performance liquid chromatography (UPLC) column (35°C). Trapping was performed using 99% Buffer A (99.9% water, 0.1% formic acid) and peptide separation with a linear gradient of solvent A (0.1% formic acid in water) and solvent B (0.075% formic acid in acetonitrile) over 90 min, at a flow rate of 300 nl/min. MS spectra were acquired in the Orbitrap using a 1 µm scan and a maximum injection time of 900 ms followed by three data-dependant MS/MS acquisitions in the ion trap (with precursor ions threshold of \>3000). The total cycle time for both MS and MS/MS acquisition was 2.4 s. Peaks targeted for MS/MS fragmentation by collision-induced dissociation were first isolated with a 2 Da window followed by normalized collision energy of 35%. Dynamic exclusion was activated where former target ions were excluded for 30 s.

Feature extraction, chromatographic/spectral alignment, data filtering, and statistical analysis were performed using Nonlinear Dynamics Progenesis LC-MS software ([www.nonlinear.com](http://www.nonlinear.com)). The raw data files were imported into the program, a sample run was chosen as a reference (usually at or near the middle of all runs in a set), and all other runs were automatically aligned to that run in order to minimize retention time (RT) variability between runs. All runs were selected for the detection of peptides with an automatic detection limit for signal-to-noise ratio of 3. Features within RT ranges of 0--25 min and 110--120 min were filtered out (these are outside the range of the peptide elution profile), as were features with a charge of ≥7. A normalization factor was then calculated for each run to account for differences in sample load between injections. The experimental design was set up to group multiple injections from each run. The algorithm then calculated and tabulated the raw and normalized abundances, the maximum fold changes and the ANOVA values for each feature in the dataset. The corresponding MS and MS/MS spectra for the features were exported as a Mascot generic file (.mgf) for database searching to perform protein identification. The .mgf files created by the Progenesis LCMS were searched in-house using the Mascot Search Algorithm (version 2.2.0). The data were searched using the Swiss protein database along with the following search parameters: enzyme, trypsin; variable modifications, carbamidomethyl (Cys), oxidation (Met), and alkylated DSP crosslinker-modified lysine (C~10~H~19~N~2~O~3~S~2~); peptide mass tolerance, ±20 ppm; fragment mass tolerance, ±0.6 Da; charge, +7; maximum missed cleavages, 3; decoy, yes; and instrument type, ESI-TRAP. The resulting search was exported as an .xml file and read into the Progenesis LC-MS software, where search hits, with at least 95% confidence, were matched to corresponding features (precursor ions and abundances). Features/peptides with nonconflicting identification match were used to provide relative quantification of protein expression. The identification of peptides/proteins and quantitative values across the various comparisons were exported as a .csv file, and further downstream data analyses were performed. The means of normalized abundances for proteins identified in three technical replicates for each tissue sample were used in subsequent analyses.

Cotinine determination from brain tissue lysate by liquid chromatography-tandem mass spectrometry {#s3G}
-------------------------------------------------------------------------------------------------

Following detergent extraction from tissue homogenates and immunopurification of β2\*-nAChR complexes with mAb295-coupled Dynabeads, the clarified lysate was frozen at −20^°^C. The lysate was thawed, and a 200 μl aliquot of each sample was subjected to organic extraction according to published methods ([@B26]) with minor modification. Briefly, the clarified tissue lysate was alkalized with 50 μl of 1 [m]{.smallcaps} NaOH and mixed with 2.5 ml of 1:1 dichloromethane/hexanes in a glass test tube and vortexed vigorously. The mixture was centrifuged for 10 min at 5000 × *g* at room temperature, and the upper organic layer was removed and placed in a clean borosilicate glass tube, then dried under a gentle stream of nitrogen at room temperature. Samples were reconstituted in 100 μl of 0.1% formic acid in water, and 10 μl of each sample was used per injection for analysis.

All liquid chromatography-tandem mass spectrometry (LC-MS/MS) identifications of cotinine were performed on an ABSciex 4000 QTrap Mass Spectrometer in positive ion mode coupled to a PerkinElmer Flexar FX-15 UPLC unit. For chromatography, solvent A was 99.9% water and 0.1% formic acid, and solvent B was 99.9% acetonitrile and 0.1% formic acid. The elution gradient was as follows: 98% solvent A, 2% solvent B from 0 to 1.8 min; 98% solvent B, 2% solvent A from 1.8 to 2.8 min; and 98% solvent A, 2% solvent B from 2.9 to 6.0 min. A selected reaction monitoring (SRM) method was developed for the quantification of cotinine present in the sample using an isotopically coded analytical standard (d-cotinine; Cerilliant Corporation). As described previously ([@B15]), the cotinine parent ion had a mass-to-charge ratio (*m*/*z*) of 177.12 at charge +1 and yielded a specific transition with major product ions of an *m*/*z* values of 80.03 and 98.02. Standard curves showed that intensities of both major product ions were linear with respect to injected cotinine \>9.5 ng/μl. Cotinine abundances for each transition from replicate injections were averaged and normalized to the total wet weight of each tissue sample in order to yield units of nanograms per gram tissue to determine nicotine use status.

Data analysis {#s3H}
-------------

SigmaPlot 13.0 and SPSS 23 (2015) were used for data organization and statistical analysis. All ligand binding data are reported in specific femtomoles/milligram protein. For proteins identified with LC-MS/MS, we took the sum of the normalized protein abundance for all proteins scoring above the 95% false discovery rate (FDR) cutoff from three technical replicates per sample and generated arithmetic means that were then log2 transformed to yield a continuous variable with a normal distribution ([@B44]). Linear regression analysis was performed using a Pearson's product moment correlation coefficient (*r*) as an indicator of significant positive correlations. Normalization using the calculated abundance of the β2 nAChR subunit (target of the IP) in each sample as the denominator was performed, and ratios relative to control conditions were compared to assess alterations in associated proteins per unit of nAChR.

Mouse cortex iTRAQ data were processed as has been described previously ([@B27]). Briefly, mean values of the reporter ion peak areas for every protein identified above the FDR cutoff were divided by the mean value for the control condition (β2^+/+^, saline) for each set and then log2 transformed to yield normalized protein expression ratios. Significant effects of nicotine exposure and mouse genotype (for the mouse samples) or mood disorder diagnosis and nicotine use (human samples) were determined with ANOVA, Holm--Sidak test, or Student's *t* test, where appropriate as determined by the nature of the experiment, with a 95% confidence interval. A general linear model (GLM) split by protein identification with multiple univariate comparisons was used to determine whether levels of individual human brain proteins \[a normally distributed (log2 fold change) continuous response variable\] that vary over multiple categorical predictor variables (nicotine, MD, both, or neither) differed in representation compared with the control condition (where the intercept is the mean of the no-nicotine exposure, no-MD diagnosis values). This was only possible for human cortical samples that were run using LFQ, in which there is a discrete interval measurement for every group. Mouse samples were run on iTRAQ in which every eight-plex experiment uses one channel as the control value, which is convoluted into the variance of the other seven reporter ion channels. Thus, the mouse GLM does not include a discrete value for the control group, since reintroducing the control group drags the regression to the origin and biases the estimates of significance.

Data are reported as mean ± SEM, with error terms specifically reported for each value.

Results {#s4}
=======

Effects of smoking and mood disorder diagnosis on nAChR number measured with \[^125^I\]-epibatidine binding {#s4A}
-----------------------------------------------------------------------------------------------------------

We measured high-affinity \[^125^I\]-epibatidine binding to particulate fractions in order to determine any effects of smoking status and mood disorder diagnosis on nAChR number in human temporal cortex. High levels of α4β2\*-nAChRs, the subtype upregulated by concentrations of nicotine typically encountered by smokers ([@B47]), are found in mammalian cortex ([@B53]). Smoking status was not included with human tissue samples, so in order to group samples appropriately, we examined the cotinine content of each sample using an SRM LC-MS/MS method with a deuterated cotinine standard. Samples were grouped according to cotinine content and α4β2\*-nAChR expression, with "nicotine users" considered as those samples with \>15 ng cotinine/g wet tissue weight. Cotinine levels present in tissue did not correlate linearly with \[^125^I\]-epibatidine binding sites (*r* ^2^ = 0.33), indicating that the postmortem tissue content of the major nicotine metabolite is useful principally for ordinal assignment of nicotine use (nicotine user or nonuser), and cannot be used to further discriminate "heavy/moderate/light" nicotine users. Based on these criteria, there were nine nicotine users and nine nonusers. Consistent with the high comorbidity between smoking and depression, the incidence of nicotine exposure was higher in individuals with a diagnosed mood disorder (six of nine were nicotine users) compared with individuals with no psychiatric diagnosis (three of nine were nicotine users). We observed a significant effect of cotinine level, our empirically determined tobacco use criterion, on nAChR number, as measured by epibatidine binding in homogenates (two-way ANOVA with Holm--Sidak multiple comparisons: *F*~(1,17)~ = 9.794, *p* = 0.007). Analysis revealed no significant effect of mood disorder diagnosis on nAChR number (*F*~(1,17)~ = 0.224, *p* = 0.673) or an interaction of nicotine × mood disorder (*F*~(1,17)~ = 0.04, *p* = 0.836) measured by equilibrium ligand binding ([Fig. 1*A*](#F1){ref-type="fig"}), which is in agreement with previous assessments of nAChR number in postmortem human cortical tissue from individuals with major depression or bipolar disorder ([@B43]; [@B10]).

![Effects of nicotine use and mood disorder on total high-affinity \[^125^I\]-epibatidine binding in cell membranes from human temporal cortex samples. ***A***, Nicotine use, determined by tissue cotinine content, has a significant effect on the number of total \[^125^I\]-epibatidine binding sites (two-way ANOVA with Holm--Sidak multiple comparisons: *F*~(1,17)~ = 9.794, *p* = 0.007), while mood disorder does not have an appreciable effect on the expression of high-affinity nAChRs in the cortex (*F*~(1,17)~ = 0.224, *p* = 0.673). ***B***, β2\*-nAChR capture was evaluated by \[^125^I\]-epibatidine binding following immunoprecipitation from human temporal cortex using mAb295-M270 Dynabeads. Error bars represent standard error of the mean.](enu0041621100001){#F1}

Immunoprecipitation of β2\*-nAChRs from human temporal cortex and identification of specific interacting proteins by tandem mass spectrometry {#s4B}
---------------------------------------------------------------------------------------------------------------------------------------------

Following the extraction of nAChR complexes from human brain tissue, we quantified specific mAb295 immunocapture of β2\*-nAChRs by measuring total \[^125^I\]-epibatidine binding sites in the solubilized tissue extract before and after incubation with mAb295-Dynabeads. In human temporal cortex samples, the recovery of β2\*-nAChRs using mAb295-Dynabeads was 74.5 ± 7.6% of input across all samples, with no effect of either smoking status or mood disorder diagnosis (*t* test, *p* = 0.32, *t* = −1.017, df = 16). In mouse cortex samples, despite fractional differences in the percentage of upregulation induced by long-term nicotine exposure as a function of genotype, capture efficiency was 60.9 ± 3.1% of input across the samples, with no significant difference in capture efficiency between the saline control and groups receiving long-term nicotine treatment (*t* test, *p* = 0.06, *t* = −2.108, df = 10), indicating that the immobilized mAb295 performed equally well across the samples regardless of differences in nAChR abundance. As expected based on epibatidine binding levels in homogenates and previously published studies, we observed a significant effect of nicotine use on the amount of β2\*-nAChR present in each sample ([Fig. 1*B*](#F1){ref-type="fig"}); however, no significant effect of mood disorder diagnosis or nicotine × mood disorder interaction was identified (two-way ANOVA: main effect, nicotine use: *F*~(1,17)~ = 18.002, *p* \< 0.0009; main effect, mood disorder: *F*~(1,17)~ = 0.236, *p* = 0.634; interaction: *F*~(1,17)~ = 0.06, *p* = 0.813).

Transgenic mice lacking expression of α4 and β2 nAChR subunits have been used previously to establish a gene dose-dependent linear relationship between α4β2\*-nAChRs and their putative associated proteins from whole mouse brain samples using an immunocapture protocol with iTRAQ-labeled peptides for quantitative proteomics ([@B27]). Such an approach used nAChR subunit heterozygous and knock-out mice to vary the abundance of nAChRs reliably and to examine relative changes in associated proteins with linear regressions to enhance confidence in identifying interacting proteins. In the human tissue samples used in this study, we observed significant variation in the total nAChR content of each sample, partially due to inherent variability, but also because of the impact of nicotine use. The measured abundance of the β2 nAChR subunit (target of the IP) as well as the abundance of α4 nAChR subunits measured by LFQ proteomics correlate extremely well with the calculated nAChR content of each sample obtained by the depletion of specific \[^125^I\]-epibatidine binding from tissue extracts (femtomoles vs β2-LFQ: *r* ^2^ = 0.89; femtomoles vs α4-LFQ: *r* ^2^ = 0.96; [Fig. 2*A*,*B*](#F2){ref-type="fig"}).

![\[^125^I\]-epibatidine binding to α4β2\*-nAChRs in human temporal cortex homogenates correlates well with β2-nAChR (***A***) and α4-nAChR (***B***) subunit abundance estimated by normalized unique peptide abundance determined by peptide LC-MS/MS.](enu0041621100002){#F2}

We identified 118 putative interacting proteins from the abundance estimates provided by proteomic analysis of mAb295 immunopurified β2\*-nAChRs from human temporal cortex. We excluded obvious contaminants (epidermal keratins, hornerin, hemoglobins, histones, cytochromes) and any protein with fewer than two unique peptides identified at a false discovery rate of 5%. With these criteria applied, we identified and quantified 78 proteins that coimmunoprecipitated with β2\*-nAChRs from human postmortem temporal cortex ([Table 1](#T1){ref-type="table"}). Of these, 42 proteins were identified as nAChR-interacting proteins in mouse cortex, and an additional 14 were isoforms of identified mouse cortex interacting proteins. An overlapping set of 36 proteins were identified in whole mouse brain as nAChR-interacting proteins, with an additional 17 isoforms of previously identified interacting proteins ([@B27]). Further, 33 of 78 proteins identified showed statistically significant correlations of protein abundance with β2-nAChR subunit abundance ([Table 2](#T2){ref-type="table"}), indicating a likely specific protein--protein interaction or physical proximity at the time of receptor extraction ([Table 3](#T3){ref-type="table"}). Functional annotation clustering of these 33 proteins using the DAVID Bioinformatics Database analysis ([@B14]) showed a significant enrichment for synaptic pathways and neuronal projection (enrichment score, 5.47). Therefore, stable receptor interactions that survive tissue solubilization are likely assembled β2\*-nAChRs, and a subset of these nAChRs may be resident in the plasma membrane of neuronal synapses. The identification of a 14-3-3 isoform previously shown to mediate α3\*nAChR trafficking to postsynaptic structures ([@B41]) indicates that some β2\* interactions are mediated on both sides of CNS synapses by this family of adaptor proteins. Based on the current dataset, it is possible that some of the captured β2\*-nAChRs reside in the postsynaptic plasma membrane, but we failed to identify additional known postsynaptic density components or associated proteins with functional annotations placing them in that neuronal subcellular compartment, so additional experiments will be required to address variations in postsynaptic versus presynaptic β2\*-nAChR-interacting proteins.

###### 

Tabulation of all proteins identified from mAb295-immunoisolated β2\*-nAChRs from human temporal cortex, indicating which proteins have been identified in mouse cortex or whole mouse brain (Iso, isoform of protein identified; GN, gene name)

  Accession_HUMAN        Description                                                                                   Mouse Ctx   Mouse Brain
  ---------------------- --------------------------------------------------------------------------------------------- ----------- -------------
  1433E                  14-3-3 protein ε GN = YWHAE                                                                   Iso         Iso
  1433G;1433F            14-3-3 protein γ GN = YWHAG                                                                   Iso         Iso
  1433S                  14-3-3 protein σ GN = SFN                                                                     Iso         Iso
  1433Z                  14-3-3 protein ζ/δ GN = YWHAZ                                                                 Iso         Yes
  ACHA4;ACHA2;ACHA6      Neuronal acetylcholine receptor subunit α4 GN = CHRNA4                                        Yes         Yes
  ACHB2                  Neuronal acetylcholine receptor subunit β2 GN = CHRNB2                                        Yes         Yes
  ACTB;ACTBM;POTEE       Actin, cytoplasmic 1 GN = ACTB                                                                Yes         Iso
  ACTC;ACTA              Actin, α cardiac muscle 1 GN = ACTC1                                                          Iso         Yes
  ACTN1;ACTN3            α-Actinin-1 GN = ACTN1                                                                        No          Yes
  ACTN2                  α-Actinin-2 GN = ACTN2                                                                        No          Yes
  ACTN4                  α-Actinin-4 GN = ACTN4                                                                        No          Iso
  ADDA                   α-Adducin GN = ADD1                                                                           No          No
  ADT1;ADT2;ADT4         ADP/ATP translocase 1 GN = SLC25A4                                                            Yes         Yes
  ALBU                   Serum albumin GN = ALB                                                                        No          No
  ANK2                   Ankyrin-2 GN = ANK2                                                                           No          Yes
  AP1B1                  AP-1 complex subunit β1 GN = AP1B1                                                            No          No
  ARP2                   Actin-related protein 2 GN = ACTR2                                                            No          Iso
  ARP3                   Actin-related protein 3 GN = ACTR3                                                            No          Yes
  ARPC3                  Actin-related protein 2/3 complex subunit 3 GN = ARPC3                                        No          Iso
  ARPC4                  Actin-related protein 2/3 complex subunit 4 GN = ARPC4                                        No          Iso
  AT1A1;AT12A            Sodium/potassium-transporting ATPase subunit α1 GN = ATP1A1                                   Iso         Iso
  AT1A2                  Sodium/potassium-transporting ATPase subunit α2 GN = ATP1A2                                   Iso         Yes
  AT1A3;AT1A4;ATP4A      Sodium/potassium-transporting ATPase subunit α3 GN = ATP1A3                                   Yes         Yes
  AT1B1                  Sodium/potassium-transporting ATPase subunit β1 GN = ATP1B1                                   Yes         Yes
  AT2B2;AT2B1            Plasma membrane calcium-transporting ATPase 2 GN = ATP2B2                                     No          No
  ATPA                   ATP synthase subunit α, mito GN = ATP5A1                                                      Yes         Yes
  ATPB                   ATP synthase subunit β, mito GN = ATP5B                                                       Yes         Yes
  BASP1                  Brain acid-soluble protein 1 GN = BASP1                                                       No          No
  CALM                   Calmodulin GN = CALM1                                                                         Yes         Yes
  CANB1                  Calcineurin subunit B type 1 GN = PPP3R1                                                      No          No
  CLH1                   Clathrin heavy chain 1 GN = CLTC SV = 5                                                       Yes         No
  CNTN1                  Contactin-1 GN = CNTN1                                                                        No          Yes
  COX2                   Cytochrome c oxidase subunit 2 GN = MT-CO2                                                    No          Yes
  COX41                  Cytochrome c oxidase subunit 4 isoform 1, mito GN = COX4I1                                    No          Yes
  COX6C                  Cytochrome c oxidase subunit 6C GN = COX6C                                                    No          Yes
  CX6B1                  Cytochrome c oxidase subunit 6B1 GN = COX6B1                                                  No          Yes
  CX7A2                  Cytochrome c oxidase subunit 7A2, mito GN = COX7A2                                            No          Yes
  DREB                   Drebrin GN = DBN1                                                                             No          Yes
  DYN1                   Dynamin-1 GN = DNM1                                                                           No          No
  E41L3                  Band 4.1-like protein 3 GN = EPB41L3                                                          No          No
  EAA1                   Excitatory amino acid transporter 1 GN = SLC1A3                                               Iso         Iso
  EAA2                   Excitatory amino acid transporter 2 GN = SLC1A2                                               Yes         Yes
  EF1A1;EF1A2            Elongation factor 1-α1 GN = EEF1A1                                                            No          No
  FCGBP                  IgGFc-binding protein GN = FCGBP                                                              No          No
  FRIH                   Ferritin heavy chain GN = FTH1                                                                No          No
  FRIL                   Ferritin light chain GN = FTL                                                                 No          No
  G3P                    Glyceraldehyde-3-phosphate dehydrogenase GN = GAPDH                                           Yes         Yes
  GBB1;GBB2;GBB3;GBB4    Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit β1 GN = GNB1                        Yes         Yes
  GELS                   Gelsolin GN = GSN                                                                             No          Yes
  GFAP                   Glial fibrillary acidic protein GN = GFAP                                                     Yes         Yes
  GNAO;GNA12             Guanine nucleotide-binding protein G(o) subunit α GN = GNAO1                                  Yes         Yes
  GPM6A                  Neuronal membrane glycoprotein M6-a GN = GPM6A                                                No          No
  H13                    Histone H1.3 GN = HIST1H1D                                                                    No          Iso
  H2A1B                  Histone H2A type 1-B/E GN = HIST1H2AB                                                         No          Yes
  H2B1M;H2B1A            Histone H2B type 1-M GN = HIST1H2BM                                                           No          Yes
  H4                     Histone H4 GN = HIST1H4A                                                                      No          Yes
  HBA                    Hemoglobin subunit α GN = HBA1                                                                No          Iso
  HBB;HBD                Hemoglobin subunit β GN = HBB                                                                 No          Yes
  HORN                   Hornerin GN = HRNR                                                                            No          No
  HS12A                  Heat shock 70 kDa protein 12A GN = HSPA12A                                                    No          Iso
  HS71L                  Heat shock 70 kDa protein 1-like GN = HSPA1L                                                  No          Iso
                                                                                                                                   
  HSPB1                  Heat shock protein β1 GN = HSPB1                                                              No          Iso
  IGHG4;IGHG2            Ig γ-4 chain C region GN = IGHG4                                                              No          Iso
  IGHM                   Ig μ chain C region GN = IGHM                                                                 No          Yes
  IGKC                   Ig κ chain C region GN = IGKC                                                                 No          Iso
  KCC2A;KCC2D            Calcium/calmodulin-dependent protein kinase type II subunit α GN = CAMK2A                     Yes         Yes
  KCC2B;KCC2G            Calcium/calmodulin-dependent protein kinase type II subunit β GN = CAMKIIB                    Yes         Yes
  MBP                    Myelin basic protein GN = MBP                                                                 Yes         Yes
  ML12A;MYL9             Myosin regulatory light chain 12A GN = MYL12A                                                 No          Iso
  MOG                    Myelin-oligodendrocyte glycoprotein GN = MOG                                                  No          No
  MPCP                   Phosphate carrier protein, mito GN = SLC25A3                                                  Yes         Yes
  MYH10                  Myosin-10 GN = MYH10                                                                          Yes         Yes
  MYH9;MYH11;MYH14       Myosin-9 GN = MYH9                                                                            Iso         Yes
  MYL6;MYL6B             Myosin light polypeptide 6 GN = MYL6                                                          Yes         Yes
  MYO5A;MYO5B            Unconventional myosin-Va GN = MYO5A                                                           No          Yes
  MYPR                   Myelin proteolipid protein GN = PLP1                                                          No          Yes
  NDUA4                  Cytochrome c oxidase subunit NDUFA4 GN = NDUFA4                                               Yes         Iso
  NDUS3                  NADH dehydrogenase \[ubiquinone\] iron-sulfur protein 3, mito GN = NDUFS3                     Yes         Yes
  NDUV2                  NADH dehydrogenase \[ubiquinone\] flavoprotein 2, mito GN = NDUFV2                            Yes         Yes
  NFL                    Neurofilament light polypeptide GN = NEFL                                                     Yes         Yes
  NFM                    Neurofilament medium polypeptide GN = NEFM                                                    Yes         Yes
  NSF                    Vesicle-fusing ATPase GN = NSF                                                                No          Yes
  ODB2                   Lipoamide acyltransferase of branched-chain α-keto acid dehydrogenase mito GN = DBT           No          Yes
  ODO2                   Dihydrolipoyllysine-residue succinyltransferase 2-oxoglutarate dehydrogenase mito GN = DLST   Yes         Yes
  QCR2                   Cytochrome b-c1 complex subunit 2, mito GN = UQCRC2                                           No          Yes
  RAB1A                  Ras-related protein Rab-1A GN = RAB1A                                                         Iso         Yes
  RL40                   Ubiquitin-60S ribosomal protein L40 GN = UBA52                                                No          No
  RO52                   E3 ubiquitin-protein ligase TRIM21 GN = TRIM21                                                No          No
  S10A7;S1A7A            Protein S100-A7 GN = S100A7                                                                   No          No
  S10A8                  Protein S100-A8 GN = S100A8                                                                   No          No
  S10A9                  Protein S100-A9 GN = S100A9                                                                   No          No
  SIR2                   NAD-dependent protein deacetylase sirtuin-2 GN = SIRT2                                        No          No
  SNP25                  Synaptosomal-associated protein 25 GN = SNAP25                                                Yes         Yes
  SPTB2;SPTB1            Spectrin β chain, nonerythrocytic 1 GN = SPTBN1                                               Yes         Yes
  SPTN1                  Spectrin α chain, nonerythrocytic 1 GN = SPTAN1                                               Yes         Yes
  SPTN2                  Spectrin β chain, nonerythrocytic 2 GN = SPTBN2                                               Iso         Iso
  SSBP                   Single-stranded DNA-binding protein, mito GN = SSBP1                                          No          No
  STX1A                  Syntaxin-1A GN = STX1A                                                                        Iso         Iso
  STX1B;STX2             Syntaxin-1B GN = STX1B                                                                        Yes         Yes
  STXB1                  Syntaxin-binding protein 1 GN = STXBP1                                                        No          Yes
  SV2A                   Synaptic vesicle glycoprotein 2A GN = SV2A                                                    No          No
  SYT1                   Synaptotagmin-1 GN = SYT1                                                                     Yes         Yes
  TBA1A,C;TBA3C,E;TBA8   Tubulin α1A chain GN = TUBA1A                                                                 Iso         Yes
  TBA1B                  Tubulin α1B chain GN = TUBA1B                                                                 Iso         Iso
  TBA4A;TBA4B;TBAL3      Tubulin α4A chain GN = TUBA4A                                                                 Yes         Yes
  TBB2A;TBB1;TBB2B       Tubulin β2A chain GN = TUBB2A                                                                 Yes         Yes
  TBB3                   Tubulin β3 chain GN = TUBB3                                                                   Yes         Yes
  TBB4A;TBB6,8;TBB8L     Tubulin β4A chain GN = TUBB4A                                                                 Yes         Yes
  TBB4B                  Tubulin β4B chain GN = TUBB4B                                                                 Yes         Yes
  TBB5                   Tubulin β chain GN = TUBB                                                                     Yes         Yes
  THY1                   Thy-1 membrane glycoprotein GN = THY1                                                         Yes         No
  TMOD2                  Tropomodulin-2 GN = TMOD2                                                                     No          Yes
  TPM4;TPM1              Tropomyosin α4 chain GN = TPM4                                                                Iso         No
  VA0D1;VA0D2            V-type proton ATPase subunit d 1 GN = ATP6V0D1                                                Yes         Iso
  VAMP3                  Vesicle-associated membrane protein 3 GN = VAMP3                                              No          Iso
  VATA                   V-type proton ATPase catalytic subunit A GN = ATP6V1A                                         Yes         Yes
  VISL1                  Visinin-like protein 1 GN = VSNL1                                                             No          No
  VPP1                   V-type proton ATPase 116 kDa subunit a isoform 1 GN = ATP6V0A1 PE = 2                         Yes         Iso

###### 

Statistical analyses indicating significance of variance with levels of the β2-nAChR subunit

  Accession_HUMAN                      ANOVA (*p*)   Peptides
  ------------------------------------ ------------- ----------
  ACTB;ACTBM;POTEE;POTEF;POTEI;POTEJ   1.10E-11      30
  S10A9                                1.67E-11      5
  ODO2                                 2.50E-11      2
  ACTC;ACTA                            1.51E-10      1
  BASP1                                2.15E-10      2
  ACTN2                                1.03E-09      5
  KCC2A;KCC2D                          2.14E-09      11
  TBA4A;TBA4B;TBAL3                    2.40E-09      3
  TBA1A;TBA1C;TBA3C;TBA3E;TBA8         2.92E-09      2
  MYH9;MYH11;MYH14                     3.28E-09      6
  S10A7;S1A7A                          3.97E-09      2
  AT1A1;AT12A                          6.35E-09      7
  AT1B1                                9.37E-09      3
  TBA1B                                6.14E-08      2
  VAMP3                                2.62E-07      1
  TBB4A;TBB6;TBB8;TBB8L                3.00E-07      10
  H2B1M;H2B1A                          3.68E-07      4
  RL40                                 8.67E-07      2
  MYH10                                1.11E-06      18
  FCGBP                                1.34E-06      19
  ODB2                                 2.48E-06      5
  COX41                                2.57E-06      2
  GELS                                 3.76E-06      10
  HS12A                                3.82E-06      4
  AT1A3;AT1A4;ATP4A                    4.09E-06      19
  TBB2A;TBB1;TBB2B                     4.12E-06      25
  ACTN1;ACTN3                          1.03E-05      19
  TBB5                                 1.04E-05      2
  ADT1;ADT2;ADT4                       1.09E-05      3
  IGHG4;IGHG2                          1.34E-05      3
  EF1A1;EF1A2                          1.53E-05      2
  DREB                                 2.67E-05      5
  COX2                                 3.01E-05      2
  CLH1                                 4.69E-05      2
  CNTN1                                5.48E-05      1
  IGKC                                 5.53E-05      1
  STX1B;STX2                           6.30E-05      6
  H13                                  8.79E-05      1
  EAA2                                 1.11E-04      2
  CX7A2                                1.19E-04      1
  ANK2                                 1.43E-04      3
  VISL1                                1.84E-04      2
  MYO5A;MYO5B                          2.45E-04      8
  ML12A;MYL9                           4.10E-04      4
  S10A8                                4.70E-04      2
  ATPA                                 5.39E-04      3
  ACTN4                                5.80E-04      5
  GFAP                                 6.13E-04      16
  ARPC4                                6.76E-04      2
  ACHB2                                7.24E-04      10
  ARPC3                                1.22E-03      1
  CANB1                                1.35E-03      1
  STXB1                                1.55E-03      3
  TBB4B                                1.58E-03      1
  TBB3                                 1.73E-03      2
  MPCP                                 2.04E-03      1
  1433Z                                2.60E-03      2
  H4                                   2.92E-03      3
  MYPR                                 2.96E-03      5
  NDUS3                                3.08E-03      1
                                                     
  GPM6A                                3.13E-03      2
  E41L3                                3.53E-03      1
  CALM                                 3.66E-03      2
  H2A1B                                4.17E-03      1
  FRIH                                 4.43E-03      3
  SPTN1                                4.48E-03      57
  GNAO;GNA12                           4.51E-03      4
  ACHA4;ACHA2;ACHA6                    5.52E-03      23
  DYN1                                 5.67E-03      4
  ARP3                                 5.99E-03      2
  SIR2                                 6.01E-03      1
  HS71L                                7.68E-03      1
  ARP2                                 8.71E-03      4
  SPTB2;SPTB1                          0.013000      48
  QCR2                                 0.019305      1
  SPTN2                                0.019379      3
  AP1B1                                0.023924      1
  VA0D1;VA0D2                          0.026761      4
  1433E                                0.028173      1
  HBB;HBD                              0.031713      4
  AT2B2;AT2B1                          0.033005      2
  HORN                                 0.037459      2
  VPP1                                 0.047673      2
  MBP                                  0.053508      6
  1433G;1433F                          0.066781      2
  TMOD2                                0.066906      1
  IGHM                                 0.067934      1
  SV2A                                 0.069290      1
  KCC2B;KCC2G                          0.070110      2
  ATPB                                 0.074512      3
  RAB1A                                0.076581      1
  FRIL                                 0.083836      1
  VATA                                 0.089288      1
  ADDA                                 0.093382      2
  AT1A2                                0.126331      3
  RO52                                 0.126544      12
  EAA1                                 0.131182      1
  1433S                                0.149390      1
  STX1A                                0.155190      4
  SNP25                                0.193139      7
  ALBU                                 0.249829      2
  HBA                                  0.254867      2
  SYT1                                 0.257254      2
  G3P                                  0.263379      3
  MYL6;MYL6B                           0.365416      5
  GBB1;GBB2;GBB3;GBB4                  0.378267      7
  TPM4;TPM1                            0.409469      3
  COX6C                                0.456303      1
  NDUA4                                0.511653      2
  CX6B1                                0.580761      1
  SSBP                                 0.640567      2
  NSF                                  0.666753      8
  MOG                                  0.744318      2
  NFM                                  0.769224      2
  THY1                                 0.778619      2
  NDUV2                                0.802323      1
  NFL                                  0.842694      5
  HSPB1                                0.941399      1

###### 

Proteins coimmunopurified with β2\*-nAChRs from postmortem human temporal cortex with abundances that correlate significantly with the abundance of the β2 nAChR subunit

  Accession     Description                                                                                         Correlation (*r*)   *p* Value   *n*
  ------------- --------------------------------------------------------------------------------------------------- ------------------- ----------- -----
  ACHB2_HUMAN   Neuronal acetylcholine receptor subunit β2                                                          1                   0           18
  ACHA4_HUMAN   Neuronal acetylcholine receptor subunit α4                                                          0.972               \<0.0009    18
  AT1B1_HUMAN   Sodium/potassium-transporting ATPase subunit β1                                                     0.889               \<0.0009    18
  AT1A3_HUMAN   Sodium/potassium-transporting ATPase subunit α3                                                     0.888               \<0.0009    18
  SNP25_HUMAN   Synaptosomal-associated protein 25                                                                  0.88                \<0.0009    18
  STX1B_HUMAN   Syntaxin-1B                                                                                         0.874               \<0.0009    18
  AT1A1_HUMAN   Sodium/potassium-transporting ATPase subunit α1                                                     0.871               \<0.0009    18
  ANK2_HUMAN    Ankyrin-2                                                                                           0.856               \<0.0009    18
  STX1A_HUMAN   Syntaxin-1A                                                                                         0.844               \<0.0009    18
  GPM6A_HUMAN   Neuronal membrane glycoprotein M6-a                                                                 0.823               \<0.0009    18
  AT2B2_HUMAN   Plasma membrane calcium-transporting ATPase 2                                                       0.781               \<0.0009    18
  GNAO_HUMAN    Guanine nucleotide-binding protein G(o) subunit α                                                   0.781               \<0.0009    18
  VPP1_HUMAN    V-type proton ATPase 116 kDa subunit a isoform 1                                                    0.777               \<0.0009    18
  MYPR_HUMAN    Myelin proteolipid protein                                                                          0.762               \<0.0009    18
  GBB1_HUMAN    Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit β1                                        0.702               0.001       18
  EAA2_HUMAN    Excitatory amino acid transporter 2                                                                 0.701               0.001       18
  VA0D1_HUMAN   V-type proton ATPase subunit d 1                                                                    0.644               0.004       18
  MYH9_HUMAN    Myosin-9                                                                                            0.631               0.005       18
  AT1A2_HUMAN   Sodium/potassium-transporting ATPase subunit α2                                                     0.609               0.007       18
  TBB5_HUMAN    Tubulin β chain                                                                                     0.576               0.012       18
  TBA1A_HUMAN   Tubulin α1A chain                                                                                   0.56                0.016       18
  1433Z_HUMAN   14-3-3 protein zeta/delta                                                                           0.548               0.019       18
  STXB1_HUMAN   Syntaxin-binding protein 1                                                                          0.526               0.025       18
  SYT1_HUMAN    Synaptotagmin-1                                                                                     0.523               0.026       18
  CLH1_HUMAN    Clathrin heavy chain 1                                                                              0.515               0.041       18
  TBA4A_HUMAN   Tubulin α4A chain                                                                                   0.514               0.029       18
  S10A7_HUMAN   Protein S100-A7                                                                                     0.511               0.03        18
  TBA1B_HUMAN   Tubulin α1B chain                                                                                   0.506               0.032       18
  RO52_HUMAN    E3 ubiquitin-protein ligase TRIM21                                                                  0.492               0.038       18
  ODO2_HUMAN    Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex   0.483               0.042       18
  TBB4A_HUMAN   Tubulin β4A chain                                                                                   0.476               0.046       18
  MYO5A_HUMAN   Unconventional myosin-Va                                                                            0.475               0.046       18
  TPM4_HUMAN    Tropomyosin α4 chain                                                                                0.473               0.047       18

High correlation indicates the identified protein is either specifically interacting with the receptor at the time of tissue lysis or is part of a complex that stays intact following extraction in Triton X-100. The cluster of proteins with correlation coefficients \<0.7 is evidence of significant enrichment of presynaptic components critical for neurotransmitter release and neuronal excitability.

Immunoprecipitation of β2\*-nAChRs from mouse cortex and identification of specific interacting proteins by tandem mass spectrometry {#s4C}
------------------------------------------------------------------------------------------------------------------------------------

As for the human samples, β2 nAChR binding sites in mouse cortex samples were immunoprecipitated by mAb295-Dynabeads and subsequently quantitated by \[I^125^\]-epibatidine binding. Binding site capture normalized to total tissue weight demonstrated significant effects of nicotine treatment and genotype ([Fig. 3](#F3){ref-type="fig"}), but not a significant interaction (two-way ANOVA; main effect, nicotine, *F*~(1,15)~ = 29.05, *p* \< 0.0009; main effect, genotype: *F*~(3,15)~ = 59.314, *p* \< 0.0009; interaction, *F*~(3,15)~ = 3.846, *p* = 0.057).

![Effects of long-term treatment with saline or 4 mg/kg/h nicotine treatment on captured \[^125^I\]-epibatidine binding sites from pooled cortex from wild-type (β2^+/+^, W), heterozygous (β2^+/−^, H), double-heterozygous (α4^+/−^β2^+/−^, DH), and knock-out (β2^−/−^, K) mice. Gene dose-dependent changes in receptor capture are apparent (two-way ANOVA; main effect, genotype: *F*~(3,15)~ = 59.314, *p* \< 0.0009), as is the upregulation produced by long-term nicotine exposure in all but the β2^−/−^ genotype groups (main effect, nicotine: *F*~(1,15)~ = 29.05, *p* \< 0.0009). Error bars represent standard error of the mean.](enu0041621100003){#F3}

Proteins identified and quantified from mouse cortex were analyzed, as has been described by [@B27], using identical criteria for inclusion and exclusion as the human tissue samples. Each mouse sample was pooled from three mice (two pools per condition × eight conditions \[nicotine-treated and untreated mice; wild-type, heterozygous, double-heterozygous, and knock-out mice\]), and we mixed the mouse tissue such that each sample contained a total of ∼0.62 g wet weight. As expected, nAChR abundance calculated from the depletion of specific \[^125^I\]-epibatidine binding sites (as femtomoles/milligram protein) correlated very well with the iTRAQ abundance ratios of α4- and β2-nAChR subunits (*r* ^2^ = 0.77 and 0.70, respectively).

Identified proteins were considered to be significant interactors according to the overall correlation of the log2-transformed ratios of mean iTRAQ reporter ions with the control sample for each set (in these samples, the control is tissue from wild-type animals; [Fig. 3](#F3){ref-type="fig"}, WT treated with saline). We observed a total of 184 coimmunopurified proteins from the mouse cortex samples, and, after the elimination of obvious contaminants and proteins identified in only one biological replicate, there were 94 proteins in common between the human and mouse experiments ([Table 4](#T4){ref-type="table"}). Of the 94 proteins identified in both biological replicates ([Table 4](#T4){ref-type="table"}), 5 were significantly correlated with β2-nAChR subunit abundance; statistical power was reduced compared with the human samples because individuals in the mouse study were pooled for measurement rather than used as biological replicates ([Table 5](#T5){ref-type="table"}). In addition, the comparative mouse nAChR-associated proteomes were collected using a peptide-labeling iTRAQ strategy, which has been shown previously to provide less comprehensive sequence coverage and fewer quantitative differences than LFQ ([@B22]). Of the 94 proteins identified in the nAChR interactome in mouse cortex, only 19 were not identified in the human cortex samples directly, or as a close isoform ([Table 4](#T4){ref-type="table"}). Further comparison to proteins associated with the β2-nAChR subunit in whole mouse brain ([@B27]) identified 37 proteins that were also immunoprecipitated from mouse and human cortex ([Table 6](#T6){ref-type="table"}). Comparing these proteins to those present in a common repository of contaminant proteins ([@B28]), 11 proteins were identified \<10 times in control studies, 7 were identified in \<100 studies, 16 were identified in \>100 control samples, and 3 were not present in the database ([Table 6](#T6){ref-type="table"}).

###### 

Tabulation of all proteins identified in common between two biological replicates of eight-plex iTRAQ-labeled β2\*-nAChRs immunoisolated with mAb295 from mouse cortex, indicating which proteins have been identified in human temporal cortex or whole mouse brain (Iso, isoform of protein identified; GN, gene name)

  Accession_MOUSE   Description                                                                                            Human Ctx   Mouse brain
  ----------------- ------------------------------------------------------------------------------------------------------ ----------- -------------
  1433T             14-3-3 protein theta GN = Ywhaq                                                                        Iso         Iso
  ACHA4             Neuronal acetylcholine receptor subunit α4 GN = Chrna4                                                 Yes         Yes
  ACHA5             Neuronal acetylcholine receptor subunit α5 GN = Chrna5                                                 Iso         Iso
  ACHB2             Neuronal acetylcholine receptor subunit β2 GN = Chrnb2                                                 Yes         Yes
  ACPM              Acyl carrier protein, mito GN = Ndufab1                                                                No          Yes
  ACTG; ACTB        Actin, cytoplasmic 2 GN = Actg1; actin, cytoplasmic 1 GN = Actb                                        Iso         Yes
  ADT1              ADP/ATP translocase 1 GN = Slc25a4 SV = 4                                                              Yes         Yes
  ADT2              ADP/ATP translocase 2 GN = Slc25a5                                                                     Yes         Yes
  AINX              α-Internexin GN = Ina                                                                                  No          Yes
  AT1A3             Sodium/potassium-transporting ATPase subunit α3 GN = Atp1a3                                            Yes         Yes
  AT1B1             Sodium/potassium-transporting ATPase subunit β1 GN = Atp1b1                                            Yes         Yes
  AT5F1             ATP synthase subunit b, mito GN = Atp5f1                                                               Iso         Yes
  ATP5H             ATP synthase subunit d, mito GN = Atp5h                                                                Iso         Yes
  ATP5I             ATP synthase subunit e, mito GN = Atp5i                                                                Iso         Yes
  ATPA              ATP synthase subunit α, mito GN = Atp5a1                                                               Yes         Yes
  ATPB              ATP synthase subunit β, mito GN = Atp5b                                                                Yes         Yes
  ATPD              ATP synthase subunit delta, mito GN = Atp5d                                                            Iso         Yes
  C1QA              Complement C1q subcomponent subunit A GN = C1qa                                                        No          No
  CALM              Calmodulin GN = Calm1                                                                                  Yes         Yes
  CLH1              Clathrin heavy chain 1 GN = Cltc                                                                       Yes         No
  CMC1              Calcium-binding mito carrier protein Aralar1 GN = Slc25a12                                             No          Yes
  CN37              2\',3\'-cyclic-nucleotide 3\'-phosphodiesterase GN = Cnp                                               No          Yes
  EAA2              Excitatory amino acid transporter 2 GN = Slc1a2                                                        Yes         Yes
  G3P               Glyceraldehyde-3-phosphate dehydrogenase GN = Gapdh                                                    Yes         Yes
  GBB1              Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit β1 GN = Gnb1                                 Yes         Yes
  GFAP              Glial fibrillary acidic protein GN = Gfap SV = 4                                                       Yes         Yes
  GLNA              Glutamine synthetase GN = Glul SV = 6                                                                  No          Yes
  GNAO              Guanine nucleotide-binding protein G(o) subunit α GN = Gnao1                                           Yes         Yes
  KCC2A             Calcium/calmodulin-dependent protein kinase type II subunit α GN = CaMKIIa                             Yes         Yes
  KCC2B             Calcium/calmodulin-dependent protein kinase type II subunit β GN = CaMKIIb                             Yes         Yes
  M2OM              Mito 2-oxoglutarate/malate carrier protein GN = Slc25a11                                               No          Yes
  MBP               Myelin basic protein GN = Mbp                                                                          Yes         Yes
  MPCP              Phosphate carrier protein, mito GN = Slc25a3                                                           Yes         Yes
  MYH10             Myosin-10 GN = Myh10                                                                                   Yes         Yes
  MYL6              Myosin light polypeptide 6 GN = Myl6                                                                   Yes         Yes
  NDUA2             NADH dehydrogenase \[ubiquinone\] 1 α subcomplex subunit 2 GN = Ndufa2                                 Iso         Yes
  NDUA4             NADH dehydrogenase \[ubiquinone\] 1 α subcomplex subunit 4 GN = Ndufa4                                 Yes         Iso
  NDUA5             NADH dehydrogenase \[ubiquinone\] 1 α subcomplex subunit 5 GN = Ndufa5                                 Iso         Yes
  NDUA6             NADH dehydrogenase \[ubiquinone\] 1 α subcomplex subunit 6 GN = Ndufa6                                 Iso         Yes
  NDUA7             NADH dehydrogenase \[ubiquinone\] 1 α subcomplex subunit 7 GN = Ndufa7                                 Iso         Yes
  NDUA9             NADH dehydrogenase \[ubiquinone\] 1 α subcomplex subunit 9, mito GN = Ndufa9                           Iso         Yes
  NDUAA             NADH dehydrogenase \[ubiquinone\] 1 α subcomplex subunit 10, mito GN = Ndufa10                         Iso         Yes
  NDUAC             NADH dehydrogenase \[ubiquinone\] 1 α subcomplex subunit 12 GN = Ndufa12                               Iso         Yes
  NDUAD             NADH dehydrogenase \[ubiquinone\] 1 α subcomplex subunit 13 GN = Ndufa13                               Iso         Yes
  NDUB3             NADH dehydrogenase \[ubiquinone\] 1 β subcomplex subunit 3 GN = Ndufb3                                 Iso         Yes
  NDUB4             NADH dehydrogenase \[ubiquinone\] 1 β subcomplex subunit 4 GN = Ndufb4                                 Iso         Yes
  NDUB5             NADH dehydrogenase \[ubiquinone\] 1 β subcomplex subunit 5, mito GN = Ndufb5                           Iso         Yes
  NDUB6             NADH dehydrogenase \[ubiquinone\] 1 β subcomplex subunit 6 GN = Ndufb6                                 Iso         Yes
  NDUB7             NADH dehydrogenase \[ubiquinone\] 1 β subcomplex subunit 7 GN = Ndufb7                                 Iso         Yes
  NDUB8             NADH dehydrogenase \[ubiquinone\] 1 β subcomplex subunit 8, mito GN = Ndufb8                           Iso         Yes
  NDUB9             NADH dehydrogenase \[ubiquinone\] 1 β subcomplex subunit 9 GN = Ndufb9                                 Iso         Yes
  NDUC2             NADH dehydrogenase \[ubiquinone\] 1 subunit C2 GN = Ndufc2                                             Iso         Yes
  NDUS1             NADH-ubiquinone oxidoreductase 75 kDa subunit, mito GN = Ndufs1                                        Iso         Yes
  NDUS2             NADH dehydrogenase \[ubiquinone\] iron-sulfur protein 2, mito GN = Ndufs2                              Iso         Yes
  NDUS3             NADH dehydrogenase \[ubiquinone\] iron-sulfur protein 3, mito GN = Ndufs3                              Yes         Yes
  NDUS4             NADH dehydrogenase \[ubiquinone\] iron-sulfur protein 4, mito GN = Ndufs4                              Iso         Yes
  NDUS5             NADH dehydrogenase \[ubiquinone\] iron-sulfur protein 5 GN = Ndufs5                                    Iso         Yes
  NDUS6             NADH dehydrogenase \[ubiquinone\] iron-sulfur protein 6, mito GN = Ndufs6                              Iso         Yes
                                                                                                                                       
  NDUS7             NADH dehydrogenase \[ubiquinone\] iron-sulfur protein 7, mito GN = Ndufs7                              Iso         Yes
  NDUS8             NADH dehydrogenase \[ubiquinone\] iron-sulfur protein 8, mito GN = Ndufs8                              Iso         Yes
  NDUV1             NADH dehydrogenase \[ubiquinone\] flavoprotein 1, mito GN = Ndufv1                                     Iso         Yes
  NDUV2             NADH dehydrogenase \[ubiquinone\] flavoprotein 2, mito GN = Ndufv2                                     Yes         Yes
  NEST              Nestin GN = Nes                                                                                        No          No
  NFH               Neurofilament heavy polypeptide GN = Nefh                                                              Iso         Iso
  NFL               Neurofilament light polypeptide GN = Nefl SV = 5                                                       Yes         Yes
  NFM               Neurofilament medium polypeptide GN = Nefm SV = 4                                                      Yes         Yes
  OCAD2             OCIA domain-containing protein 2 GN = Ociad2                                                           No          Yes
  ODO2              Dihydrolipoyl-lysine residue succinyltransferas 2-oxoglutarate dehydrogenase complex, mito GN = Dlst   Yes         Yes
  ODPA              Pyruvate dehydrogenase E1 component subunit α, somatic form, mito GN = Pdha1                           No          Yes
  ODPB              Pyruvate dehydrogenase E1 component subunit β, mito GN = Pdhb                                          No          Yes
  PHB               Prohibitin GN = Phb                                                                                    No          Yes
  PHB2              Prohibitin-2 GN = Phb2                                                                                 No          Yes
  RAB3A             Ras-related protein Rab-3A GN = Rab3a                                                                  Iso         Yes
  SFXN3             Sideroflexin-3 GN = Sfxn3                                                                              No          Yes
  SNP25             Synaptosomal-associated protein 25 GN = Snap25                                                         Yes         Yes
  SPTB2             Spectrin β chain, nonerythrocytic 1 GN = Sptbn1                                                        Yes         Yes
  SPTN1             Spectrin α chain, nonerythrocytic 1 GN = Sptan1 SV = 4                                                 Yes         Yes
  STX1B             Syntaxin-1B GN = Stx1b                                                                                 Yes         Yes
  SYPH              Synaptophysin GN = Syp                                                                                 No          No
  SYT1              Synaptotagmin-1 GN = Syt1                                                                              Yes         Yes
  TBA4A             Tubulin α4A chain GN = Tuba4a                                                                          Yes         Yes
  TBB2A             Tubulin β2A chain GN = Tubb2a                                                                          Yes         Yes
  TBB3              Tubulin β3 chain GN = Tubb3                                                                            Yes         Yes
  TBB4A             Tubulin β4A chain GN = Tubb4a                                                                          Yes         Yes
  TBB4B             Tubulin β4B chain GN = Tubb4b                                                                          Yes         Yes
  TBB5              Tubulin β5 chain GN = Tubb5                                                                            Yes         Yes
  THY1              Thy-1 membrane glycoprotein GN = Thy1                                                                  Yes         No
  TPM3              Tropomyosin α3 chain GN = Tpm3                                                                         Iso         No
  VA0D1             V-type proton ATPase subunit d 1 GN = Atp6v0d1                                                         Yes         Iso
  VATA              V-type proton ATPase catalytic subunit A GN = Atp6v1a                                                  Yes         Yes
  VDAC1             Voltage-dependent anion-selective channel protein 1 GN = Vdac1                                         No          Yes
  VDAC2             Voltage-dependent anion-selective channel protein 2 GN = Vdac2                                         No          Yes
  VIME              Vimentin GN = Vim                                                                                      No          Yes
  VPP1              V-type proton ATPase 116 kDa subunit a isoform 1 GN = Atp6v0a1                                         Yes         Iso

###### 

β2\*-nAChR interacting proteins identified by iTRAQ analysis of receptors isolated from transgenic mouse cortex receiving long-term treatment with nicotine and not receiving nicotine treatment (GN, gene name)

  Accession                 Description                                                                                   Correlation (*r*)   *p* Value
  ------------------------- --------------------------------------------------------------------------------------------- ------------------- -----------
  sp\|O70174\|ACHA4_MOUSE   Neuronal acetylcholine receptor subunit α4 OS = Mus musculus GN = Chrna4 PE = 2 SV = 2        0.97                \<0.0009
  sp\|Q2MKA5\|ACHA5_MOUSE   Neuronal acetylcholine receptor subunit α5 OS = Mus musculus GN = Chrna5 PE = 2 SV = 1        0.91                \<0.0009
  sp\|Q9ERK7\|ACHB2_MOUSE   Neuronal acetylcholine receptor subunit β2 OS = Mus musculus GN = Chrnb2 PE = 2 SV = 1        1                   \<0.0009
  sp\|Q6PIC6\|AT1A3_MOUSE   Sodium/potassium-transporting ATPase subunit α3 OS = Mus musculus GN = Atp1a3 PE = 1 SV = 1   0.55                0.042
  sp\|Q62277\|SYPH_MOUSE    Synaptophysin OS = Mus musculus GN = Syp PE = 1 SV = 2                                        0.59                0.026

Similar to the results from human cortex samples, presynaptic elements related to vesicle fusion (synaptophysin) and neuronal excitability (ATP1A3) are significantly correlated with nAChR levels.

###### 

List of proteins identified in three independent proteomic studies: human and mouse cortex (current study) and whole mouse brain ([@B27]) (GN, gene name)

  Accession   Description                                                                                        No. of experiments (found/total)
  ----------- -------------------------------------------------------------------------------------------------- ----------------------------------
  ACHA4       Neuronal acetylcholine receptor subunit α4 GN = Chrna4                                             0/411
  ACHB2       Neuronal acetylcholine receptor subunit β2 GN = Chrnb2                                             0/411
  ADT1        ADP/ATP translocase 1 GN = Slc25a4                                                                 195/411
  ADT2        ADP/ATP translocase 2 GN = Slc25a5                                                                 223/411
  AT1A3       Sodium/potassium-transporting ATPase subunit α3 GN = Atp1a3                                        101/411
  AT1B1       Sodium/potassium-transporting ATPase subunit β1 GN = Atp1b1                                        1/411
  ATPA        ATP synthase subunit α, mito GN = Atp5a1                                                           210/411
  ATPB        ATP synthase subunit β, mito GN = Atp5b                                                            211/411
  CALM        Calmodulin GN = Calm1                                                                              133/411
  EAA2        Excitatory amino acid transporter 2 GN = Slc1a2                                                    2/411
  G3P         Glyceraldehyde-3-phosphate dehydrogenase GN = GAPDH                                                248/411
  GBB1        Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit β1 GN = Gnb1                             59/411
  GFAP        Glial fibrillary acidic protein GN = GFAP                                                          73/411
  GNAO        Guanine nucleotide-binding protein G(o) subunit α GN = Gnao1                                       42/411
  KCC2A       Calcium/calmodulin-dependent protein kinase type II subunit α GN = CaMKIIa                         7/411
  KCC2B       Calcium/calmodulin-dependent protein kinase type II subunit β GN = CaMKIIb                         7/411
  MBP         Myelin basic protein GN = Mbp                                                                      0/411
  MPCP        Phosphate carrier protein, mito GN = Slc25a3                                                       130/411
  MYH10       Myosin-10 GN = Myh10                                                                               166/411
  MYL6        Myosin light polypeptide 6 GN = Myl6                                                               190/411
  NDUS3       NADH dehydrogenase \[ubiquinone\] iron-sulfur protein 3, mito GN = Ndufs3                          19/411
  NDUV2       NADH dehydrogenase \[ubiquinone\] flavoprotein 2, mito GN = Ndufv2                                 3/411
  NFL         Neurofilament light polypeptide GN = Nefl                                                          Not in database
  NFM         Neurofilament medium polypeptide GN = Nefm                                                         85/411
  ODO2        Dihydrolipoyllysine-res succinyltransferase 2-oxoglutarate dehydrogenase complex, mito GN = Dlst   57/411
  SNP25       Synaptosomal-associated protein 25 GN = Snap25                                                     0/411
  SPTB2       Spectrin β chain, nonerythrocytic 1 GN = Sptbn1                                                    143/411
  SPTN1       Spectrin α chain, nonerythrocytic 1 GN = Sptan1                                                    161/411
  STX1B       Syntaxin-1B GN = Stx1b                                                                             0/411
  SYT1        Synaptotagmin-1 GN = Syt1                                                                          0/411
  TBA4A       Tubulin α4A chain GN = Tuba4a                                                                      377/411
  TBB2A       Tubulin β2A chain GN = Tubb2a                                                                      372/411
  TBB3        Tubulin β3 chain GN = Tubb3                                                                        Not in database
  TBB4A       Tubulin β4A chain GN = Tubb4a                                                                      366/411
  TBB4B       Tubulin β4B chain GN = Tubb4b                                                                      376/411
  TBB5        Tubulin β5 chain GN = Tubb5                                                                        Not in database
  VATA        V-type proton ATPase catalytic subunit A GN = Atp6v1a                                              62/411

Numbers in the right hand column represent the number of times each protein has been identified in control studies designed to evaluate background contaminants ([@B28]).

Effects of nicotine exposure and mood disorder on nAChR-associated proteins isolated from human temporal cortex {#s4D}
---------------------------------------------------------------------------------------------------------------

To identify changes in the β2\*-nAChR-associated proteome due to nicotine exposure status or mood disorder, we compared the abundance ratios for every protein identified in each sample and performed GLM analysis to identify significant changes. Of the 33 putative interacting proteins identified following immunoprecipitation of β2\*-nAChRs from human cortex ([Table 3](#T3){ref-type="table"}), 14 proteins differed in interaction as a result of tobacco use, as measured by a shift in the ratio of the interacting protein to nAChR number between nonexposed and tobacco-exposed individuals, with two additional protein (14-3-3ζ and ATP1A2) that showed a significant nicotine × mood disorder interaction ([Fig. 4*A*](#F4){ref-type="fig"}, [Table 7](#T7){ref-type="table"}). None of the interactions were significantly altered by mood disorder alone ([Table 7](#T7){ref-type="table"}). Several of the changes in associated protein abundance appear to be affected more significantly by the combination of nicotine use and mood disorder ([Fig. 4](#F4){ref-type="fig"}, open triangles) despite the nonsignificant interaction term calculated from the dataset as a whole. Normalizing protein abundance to β2 nAChR content within each sample identified an independent set of five proteins that were significantly altered by nicotine use (Fig. [4*B*](#F4){ref-type="fig"}, Table [8](#T8){ref-type="table"}); again, we did not identify significant differences by mood disorder diagnosis.

![***A***, Representation of the log2-normalized fold change in β2\*-nAChR-associated proteins in human temporal cortex relative to the non-nicotine, non-MD group average. The graph shows nAChR-associated proteins whose expression is significantly impacted by nicotine, MD, or an interaction, according to GLM. Group means above zero are upregulated by nicotine exposure, indicating that as nAChR levels increase, so do the levels of those proteins. Increases in excess of the log2 fold change for the α4- and β2-nAChR subunits indicate a superstoichiometric shift. ***B***, Log2 protein abundance normalized to within-sample β2-nAChR protein content for five proteins that showed a significant shift with nicotine use. Normalization demonstrates the change in protein expression per molecule of the nAChR β2-subunit in human cortical samples. For these samples, LFQ proteomics allows the comparison of protein levels, even when the variation in total abundance across treatments is small. Normalization to an internal standard in each condition (β2-subunit levels) allows the measurement of more discrete changes than are apparent from fold change estimates.](enu0041621100004){#F4}

###### 

β2\*-nAChR-associated proteins with abundances that are significantly affected by nicotine use and/or mood disorder status in human temporal cortex

  Accession     Description                                         Significant effect        *F*                                        *p* Value
  ------------- --------------------------------------------------- ------------------------- ------------------------------------------ --------------
  1433Z_HUMAN   14-3-3 protein zeta/delta                           MD x Nicotine             *F*~(1,17)~ = 4.943                        0.043
  ACHA4_HUMAN   Neuronal acetylcholine receptor subunit α4          Nicotine                  *F*~(1,17)~ = 16.596                       \<0.0009
  ACHB2_HUMAN   Neuronal acetylcholine receptor subunit β2          Nicotine                  *F*~(1,17)~ = 12.881                       \<0.0009
  AT1A1_HUMAN   Sodium/potassium-transporting ATPase subunit α1     Nicotine                  *F*~(1,17)~ = 7.460                        0.016
  AT1A2_HUMAN   Sodium/potassium-transporting ATPase subunit α2     Nicotine, MD × nicotine   *F*~(1,17)~ = 5.749; *F*~(1,17)~ = 4.740   0.031; 0.047
  AT1A3_HUMAN   Sodium/potassium-transporting ATPase subunit α3     Nicotine                  *F*~(1,17)~ = 5.820                        0.03
  AT1B1_HUMAN   Sodium/potassium-transporting ATPase subunit β1     Nicotine                  *F*~(1,17)~ = 7.537                        0.016
  AT2B2_HUMAN   Plasma membrane calcium-transporting ATPase 2       Nicotine                  *F*~(1,17)~ = 13.246                       0.003
  GNAO_HUMAN    Guanine nucleotide-binding protein G(o) subunit α   Nicotine                  *F*~(1,17)~ = 5.077                        0.041
  MYPR_HUMAN    Myelin proteolipid protein                          Nicotine                  *F*~(1,17)~ = 8.779                        0.01
  S10A7_HUMAN   Protein S100-A7                                     Nicotine                  *F*~(1,17)~ = 5.850                        0.03
  SNP25_HUMAN   Synaptosomal-associated protein 25                  Nicotine                  *F*~(1,17)~ = 11.990                       0.004
  STX1A_HUMAN   Syntaxin-1A                                         Nicotine                  *F*~(1,17)~ = 11.506                       0.004
  STX1B_HUMAN   Syntaxin-1B                                         Nicotine                  *F*~(1,17)~ = 11.792                       0.004
  VPP1_HUMAN    V-type proton ATPase 116 kDa subunit a isoform 1    Nicotine                  *F*~(1,17)~ = 5.946                        0.029

Nicotine use has the largest statistical effect observed in terms of its impact on β2\*-nAChR expression and the abundance of associated proteins. Only two proteins (14-3-3ζ and ATP1A2) show a significant interaction between nicotine use and mood disorder.

###### 

β2\*-nAChR-associated proteins that show a significant effect of nicotine use on their "per-β2" abundance from human temporal cortex

  Accession     Description                                                    Significant effect   *F*                    *p* Value
  ------------- -------------------------------------------------------------- -------------------- ---------------------- -----------
  GBB1_HUMAN    Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit β1   Nicotine             *F*~(1,17)~ = 10.085   0.007
  RO52_HUMAN    E3 ubiquitin-protein ligase TRIM21                             Nicotine             *F*~(1,17)~ = 5.676    0.031
  STX1A_HUMAN   Syntaxin-1A                                                    Nicotine             *F*~(1,17)~ = 5.375    0.036
  TPM4_HUMAN    Tropomyosin α4-chain                                           Nicotine             *F*~(1,17)~ = 5.911    0.029
  VAOD1_HUMAN   V-type proton ATPase subunit d 1                               Nicotine             *F*~(1,17)~ = 6.700    0.021

These proteins have abundance indices that correlate significantly with levels of β2-nAChR, but the effect of nicotine is apparent only when protein content is normalized to total β2-nAChR levels, suggesting that their expression does not track linearly with increases in nAChR due to nicotine-induced upregulation and likely represent limiting interactions.

Effects of nicotine exposure on nAChR-associated proteins isolated from mouse cortex {#s4E}
------------------------------------------------------------------------------------

In the mouse iTRAQ data, GLM analysis did not identify a significant effect of nicotine on any of the nAChR-associated proteins with expression indices significantly correlated with β2-nAChR abundance. Although nicotine exposure did increase the abundance of the α4- and β2-nAChR subunits, the increase was only marginally significant (Chrna4: *F*~(1,13)~ = 4.93, *p* = 0.06; Chrnb2: *F*~(1,13)~ = 4.67, *p* = 0.07), likely due to the small number of pools included in the analysis. In addition, the overall *n* size of the experiment was reduced because the β2-nAChR subunit abundance from the control groups is used as the denominator in their ratiometric quantitation, and is not included as a correlate to avoid bias due to artificially small errors on the calculated intercept. This ratiometric quantitation also prevents normalization to β2-nAChR subunit abundance within each sample, so a depiction of change relative to "per unit" β2 is not possible. Analysis of genotype effects on iTRAQ-labeled nAChR peptides with GLM showed significance for all three subunits identified, as follows: Chrna4: *F*~(3,13)~ = 16.43, *p* = 0.001; Chrna5: *F*~(3,13)~ = 8.87, *p* = 0.009; Chrnb2: *F*~(3,13)~ = 12.78, *p* = 0.003.

Discussion {#s5}
==========

In this study, we examined the effects of tobacco use and mood disorder on the expression of α4β2\*-nAChRs and their associated proteins in postmortem human cortex. We also used experiments in mice to determine the effects of nicotine alone on the associated proteome. Repeated or prolonged nicotine exposure increases α4β2\*-nAChR number in heterologous expression systems, animal models, and human tissue (for review, see [@B29]). In addition, the changes in α4β2\*-nAChR content after long-term exposure to nicotine are brain region and cell type specific, with cortical regions among those most reproducibly affected in both mouse and human ([@B24]; [@B35]). Further, a substantial body of evidence points to a cholinergic contribution to the etiology and expression of affective disorders (for review, see [@B31]), and that β2\*-nAChR occupancy by endogenous ACh is significantly increased by current or past episodes of major depressive or bipolar disorder ([@B43]; [@B10]). Studies in mouse models indicate that even acute dysregulation of cholinergic neurotransmission can elicit changes in affective states, and that long-term manipulation of acetylcholine levels leads to behavioral responses that are commonly indicative of mood disorders, specifically depression- and anxiety-like behaviors ([@B34]). Identifying the interactions of α4β2\*-nAChRs with other synaptic proteins and functional regulators could therefore identify the novel elements of neuronal plasticity underlying the acquisition of nicotine tolerance and dependence, as well as improve understanding of how cholinergic regulation of mood is accomplished in the CNS.

For this study we measured cotinine levels in the brain tissue lysate (containing all of the cytosolic and interstitial fluid components) to establish nicotine/tobacco use status for each sample. After organizing the samples according to nicotine use and mood disorder status, we observed that the levels of α4β2\*-nAChRs measured by radioligand binding with \[^125^I\]-epibatidine were consistent with significant receptor upregulation due to nicotine use. The levels of α4- and β2-nAChR subunits measured by label-free quantitative proteomics were consistent with the changes observed with ligand binding. These results indicated that, when performed appropriately, quantitative immunopurification and proteomics is a valid method for evaluating changes in nAChR expression.

A different form of quantitative proteomics (iTRAQ) was used to assess changes in α4β2\*-nAChRs and associated proteins from transgenic mouse tissue. iTRAQ uses amine-reactive isobaric labels to facilitate the ratiometric quantitation of peptides from multiplexed samples in a complex mixture ([@B52]). Multiplexed iTRAQ proteomics has been used previously with nAChR subunit transgenic mice to validate the approach for the untargeted identification of putative nAChR-associated proteins ([@B27]). In this project, we used iTRAQ to identify interacting proteins that are altered in their association with β2\*-nAChR due to long-term nicotine treatment. It was our goal to test the hypothesis that a core set of α4β2\* interacting partners would be conserved in the cortex from mouse to human, and that the identification of these complexes could guide future studies geared toward understanding nAChR regulation and function.

We took advantage of the inherent variability in β2\*-nAChR abundance across samples (due to either individual differences and/or nicotine use status in the case of the human samples, and genetic control of nAChR abundance and nicotine exposure in the mouse samples) to match linear relationships of protein abundance indices with the measured abundance of β2-nAChRs, providing confidence that the proteins coimmunopurifying with the β2\*-nAChRs interact in a meaningful context. Abundance correlations would be expected to be random and nonsignificantly correlated if interactions were nonspecific. We observed a high level of overlap between human and mouse cortical samples of signaling complexes coimmunoprecipitated with β2\*-nAChRs.

The functional roles of nAChRs as neuromodulators on presynaptic terminals of many different neuronal types have been described in numerous previous studies (for review, see [@B1]). Evidence in the current study from bottom-up quantitative proteomic analysis of α4β2\*-nAChR-associated proteins identified in human and mouse cortical tissue not only supports a presynaptic role for these receptors, but assigns additional proteins with known roles in neurotransmitter release and neuronal excitability that begin to describe the composition of specific signaling complexes assembled with nAChRs. Specifically, components of the presynaptic active zone and the SNARE complex (syntaxin1B, syntaxin1A, syntaxin binding protein-1, SNAP25, and synaptotagmin) were identified with significant expression correlations with β2-nAChR subunits in the human temporal cortex samples; the same core set of proteins were also identified in the mouse cortex iTRAQ analysis. Smaller sample size due to the pooling of individual mice for analyses limited statistically significant correlation to synaptophysin; however, identification across two species with differing exposure modalities increases confidence that interaction of the set of nAChR-associated proteins identified from human brain are altered as a result of nicotine exposure.

Of the 17 proteins that were identified previously with iTRAQ using stringent criteria for dose relationships in mice with varying nAChR genotype in whole mouse brain ([@B27]), 8 were identified in both mouse and human cortex in the current study (α4- and β2-nAChR subunits, CaMKIIα, spectrin α and β, myosin 10, tubulin β3, and GFAP; [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). Syntaxin 1B, synaptotagmin 1, syntaxin binding protein 1, and several 14-3-3 isoforms were also identified in all three datasets. These proteins, although clearly identified in the nAChR-associated proteome from whole mouse brain, did not meet the stringent criteria for variance with gene dose. One possibility is that each of these proteins is limiting in the compartment (synaptic or ER) in which it interacts with nAChRs, and that the interaction is functional and transient (during vesicle recruitment or release, or during nAChR assembly), so it does not scale with nAChR number. Of those proteins that were not identified in the current study, several proteins were represented by different isoforms or by other proteins with related functions. For example, while the current study did not identify CaMKIIγ, the β-isoform was identified in both mouse and human cortical samples, perhaps because the γ-isoform is more highly expressed in other brain regions, and the β-isoform in enriched in cortex.

Many subtypes of nAChRs have been identified as presynaptic heteroreceptors that can directly influence neurotransmitter release, and the identification of SNARE complex proteins as significant nAChR interactors in both the mouse and human tissue samples suggests a functional interaction between α4β2\*-nAChRs and neurotransmitter release machinery. Minimally, this association indicates that some α4β2\*-nAChRs are extremely close to sites on presynaptic terminals where neurotransmitter release is actively taking place. Such close physical association suggests that nAChRs may exert some modulatory influence on neurotransmitter release independently of action potential arrival or frequency, and highlights their potential role as a "fine-tuning" influence on activity at highly specialized synapses. It is also possible that the significant interaction of synaptic vesicle components with β2\*-nAChRs indicates the presence of α4β2\*-nAChR-mediated neurotransmitter release process from perisynaptic sites, similar to what has been proposed for α7 and α3\* nAChRs in the chick ciliary ganglion ([@B5]). Interestingly, the degree of interaction between syntaxin1A and β2\*-nAChRs was reduced in human cortical tissue from nicotine users, raising the possibility that long-term nicotine use promotes a functional reorganization of presynaptic nAChR signaling complexes. The family of 14-3-3 isoforms have multiple functions (for review, see [@B55]), including acting as chaperones and adaptors that mediate complex protein--protein interactions, and have been shown to facilitate nAChR trafficking and assembly of α3\* nAChRs at postsynaptic sites in the ciliary ganglion ([@B41]). The current finding showing that 14-3-3ζ interacts with β2\*-nAChRs suggests that adapter protein interactions are critical determinants of trafficking and functional regulation of nAChRs on both presynaptic and postsynaptic plasma membranes and that these interactions are likely to be context specific. Nicotine use may also induce restructuring of postsynaptic elements of cholinergic synapses, but in this study we did not reliably identify components of larger postsynaptic complexes associated with β2\*-nAChRs. It is possible that in the cortex of both mice and humans, the postsynaptic β2\*-nAChR interactome is more dynamic and less likely to survive the conditions used for isolating nAChRs in this study; additional studies using methods for enriching and isolating nAChRs from specific subcellular neuronal compartments is necessary to address this question.

The proteoglycan agrin, which contributes to the orchestration of nAChR clustering at the neuromuscular junction (NMJ; [@B50]), has also been identified as an inhibitor of α3-containing Na/K ATPases ([@B13]). We identified α3 Na/K-ATPase as a β2\*-nAChR-interacting protein from both human and mouse cortical tissues. Its abundance was upregulated along with the β2\*-nAChR subunit in the human samples with nicotine treatment, as evidenced by the similar ratio of α3 Na/K-ATPase/β2-nAChR levels across treatment groups. This parallel increase suggests that aspects of presynaptic neuronal excitability are changed by long-term nicotine treatment beyond the alterations in excitation due to prolonged nAChR desensitization or other mechanisms of agonist-induced functional changes. An additional link between altered Na/K-ATPase activity and mood disorder is found in the Myshkin mouse model, which harbors a loss-of-function mutation in the α3Na/K-ATPase and exhibits behavioral hallmarks of the manic phase of bipolar disorder that are responsive to traditional pharmacotherapies (valproate, lithium) as well as inhibitors of downstream signaling linked to α3Na/K-ATPase ([@B20]). Postsynaptic nAChRs at the NMJ copurify with the α2Na/K-ATPase subunit ([@B12]; [@B46]), and we observe significant correlation here of α2-Na/K ATPase abundance with β2\*-nAChRs. Genetic risk variants for mood disorders have been found in the Na/K ATPase α2- and α3-loci ([@B46]), highlighting the potential functional interactions between nAChRs and Na/K-ATPases in the CNS that may also impact lifetime risk for developing mood disorders. The fact that we observe α4β2\*-nAChRs associated with Na/K-ATPase subunits as well as SNARE complex machinery and other mediators of synaptic activity leads us to consider that presynaptic nAChRs may exist as part of a core activity complex with substantial homology to what has been shown to exist postsynaptically at the NMJ ([@B12]; [@B46]). Further experiments and fine-detailed structural analysis of presynaptic nAChR scaffolds in the CNS will, it is hoped, add to this concept of conserved cholinergic regulation via novel functions of proteins previously unknown as functional regulators of nAChRs.

Another specific β2-interactor of interest for additional study is the protein TRIM21, an E3 ubiquitin ligase with roles in cell cycle progression and immune signaling ([@B49]). Muscle-type nAChR turnover is at least partially dependent on the targeted autophagy of ubiquitinated receptors ([@B19]), and the role of the ubiquitin--proteasome system in the trafficking and stability of α3\* nAChRs has been shown in both cell lines ([@B40]) and rodent neurons ([@B48]). Different E3 ubiquitin ligases were determined to be critical mediators of the selective degradation of ubiquitinylated muscle and α3\* nAChR subtypes in the previous studies (TRIM63 and CHIP, respectively); our identification of TRIM21 as a β2\*-nAChR-associated E3 ubiquitin ligase in human cortical neurons indicates that future studies are warranted to determine whether it is a specific regulator of α4β2\*-nAChR turnover.

A recent publication presents a hypothesis that nAChRs, including β2\*-nAChR, may possess a structural motif that promotes functional interaction with Gα subunits of the heterotrimeric G-protein complex ([@B18]). Earlier studies using proteomic methods to interrogate β2-nAChR subunit interactions identified Gα subunits as a reliable associated protein in mouse brain tissue lysate ([@B17]). Here we show that β2\*-nAChRs from human cortical tissue also associate with Gα subunits (particularly, the Gα~o~ subtype), and that nicotine use significantly affects their abundance index across sample groups. Whether this change in Gα~o~ interaction with β2\*-nAChRs is functionally relevant to the physiological response to short-term or long-term nicotine use remains to be elucidated, but our results supporting the earlier discovery that a β2--Gα interaction is taking place provides considerable support for additional studies aimed at dissecting the roles of metabotropic signaling via nAChR ion channels.

Of the identified proteins, only two, 14-3-3ζ and ATP1A2, showed a significant nicotine × mood disorder interaction. As noted above, the Na/K ATPase is critically involved in neuronal energetics and at the presynaptic terminal and variants in the ATPase have been associated with mood disorders ([@B46]). In contrast, 14-3-3 proteins are involved in chaperoning nAChRs from the endoplasmic reticulum to the cell surface, and this chaperone function is regulated by protein phosphorylation ([@B16]). The significant nicotine × mood disorder interaction in the association of these proteins with β2\*-nAChRs may therefore suggest that nAChR trafficking is altered differentially by nicotine exposure in individuals with mood disorders. This is an intriguing hypothesis that can be evaluated in future studies.

Our data have identified several proteins involved in the regulation of neuronal excitation and neurotransmitter exocytosis that are proximally associated with nAChRs in humans and mice, and are significantly affected by physiological conditions known to impact the expression of nAChRs themselves. While mood disorders have been demonstrated to involve significant contributions from cholinergic components, the impacts of smoking status on nAChR expression as well as the expression of interacting proteins appears to be a much more powerful perturbation. It is possible that different mood disorders (i.e., bipolar disorder vs major depression vs general anxiety disorder) are also representative of distinct entities with respect to cholinergic dysfunction that would benefit from additional exploration of discrete changes in the nAChR-associated proteome. These results indicate that the regulation of nAChRs and other membrane signaling complexes in skeletal muscle share core regulatory and functional interactions with β2\*-neuronal nAChRs, albeit with different proteins that serve functionally similar roles. This study shows that proteomic methods are a powerful tool to identify proteins associated with nAChRs. Proteomic strategies were different for the human and mouse β2-nAChR-interacting protein identifications, and, despite obvious technical distinctions, strengths, and weaknesses, remarkably conserved protein complexes were found to be associated with assembled receptors. Additional proteomic studies aimed at a finer dissection of cell type-specific nAChR interactions may identify more targets that regulate and are regulated by nAChR activity to provide additional mechanistic insight into the contribution of cholinergic dysfunction in neurological disorders.
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Synthesis {#s6}
=========

The decision was a result of the Reviewing Editor Alfonso Araque and the peer reviewers coming together and discussing their recommendations until a consensus was reached. A fact-based synthesis statement explaining their decision and outlining what is needed to prepare a revision is listed below. The following reviewers agreed to reveal their identity: Michele Jacob, Darwin Berg

The reviewers have found merit and interest on the findings reported. I concur with the reviewers\' comments expressing the interest, novelty and quality of the study. However, they also expressed some concerns about several issues that need to be addressed and clarified. I also consider pertinent the concerns expressed. I believe that addressing those concerns, which will definitely improve the manuscript, is necessarily required to properly support the conclusions.

Specific comments of the reviewers:

Reviewer 1.

This manuscript addresses the important question of how do exposure to tobacco/nicotine and depressive mood disorders alter the levels of b2\*nAChRs and their associated protein interactome in the human brain. They use an unbiased proteomic screen of postmortem human temporal cortex. For comparison to human b2 interactors, the study makes clever use of b2\*nAChR mutant mice, heterozygous and homozygous deletions versus wild-type b2, plus versus minus nicotine exposure. The findings identify a relatively small number of proteins that both co-precipitate with b2 and show significantly altered levels in tobacco users versus non-users. Only two putative interactors, 14-3-3zeta and ATP1A2 differed significantly with both tobacco use and mood disorders. This finding extends reports that nicotine exposure alters other Na/K-ATPase isoforms in skeletal muscle. The current findings also extend reports that selected nAChR subunits link with particular isoforms of two other putative interactors (TRIM21, an E3 ubiquitin ligase and a Galpha subtype). However, the current study does not confirm the interactions and it does not advance the functional significance of the putative interactions.

It is not clear whether the altered levels of putative interactors found in the tobacco users is caused by the increased b2 and a4 levels (more physical binding sites) or by altered activity resulting from the increased cholinergic tone. It is also possible that tobacco users have altered levels of other nAChRs such as a7 whose activation may be the cause of the changes in the presynaptic proteins known to function in neuronal excitability.

Strengths:

1-) Unbiased proteomic approach; 14/33 putative interactors of b2 showed altered levels in postmortem tobacco users versus non-users; 2 of these correlated significantly with both tobacco use and mood disorders.

2-) Make excellent use of mouse mutants for shared changes with human b2\*nAChR putative interactors. 8 proteins identified in both human and mouse cortex as shared b2\*nAChR putative interactors, but did not vary with gene dosage

3-) use nicotine metabolite levels in postmortem human temporal cortex to evaluate tobacco usage

4-) Table 6 is a good inclusion for putative interactors often seen in control databases

Weaknesses:

1-) The mouse b2\*nAChR co-precipitated proteins were not significantly altered by nicotine exposure after correcting for b2 abundance, as done for the human data, making it difficult to conclude the significance of the changes found in the human studies. Are the changed levels in humans caused by nicotine or by other factors such as altered activity in the cortical circuits.

2-) 14-3-3 zeta co-precipitated with human b2 but not mouse. What is the explanation for this difference?

3-) Cross linkers were used to stabilize labile interactions prior to detergent extraction but this could cause co-precipitation of neighboring proteins. It is important to discuss the size of the cross-linker and how it may alter the results. Some of the co-precipitated proteins are glial and others are presynaptic active zone and synaptic vesicle proteins, establishing the importance for testing the interactions by independent biochemical assays, without the cross-linker. Some statements (p.16, last sentence of 1st paragraph) should be modified \"stable receptor interactions that survive tissue solubilization are with functional b2\*nAChRs resident in the plasma membrane of neuronal synapses\". Most of this (underlined parts) was not demonstrated. Similarly, last paragraph of discussion needs to be modified for same reasons.

4-) they conclude that the b2\*nAChRs are presynaptic based on putative interactions with presynaptic neurotransmitter release proteins but they cannot rule out intracellular distribution of the cross-linked co-precipitated proteins and a postsynaptic localization of surface b2\*nAChRs.

5-) need to show p values and state statistic tests used in Figure legends.

6-) In Fig. 3, why does the het show a greater increase in b2 levels with nicotine than the wild type? Fig. 3 legend has a typo, a2 is a4.

7-) Why were only female mice used for this study?

8-) Were protease inhibitors added during the homogenization and cross-linking?

Reviewer 2.

This manuscript reports on proteins associated with nicotinic acetylcholine receptors (nAChRs) identified by immunoprecipitation of the receptors followed by quantitative proteomic analysis of the associated components. The major focus of the report is to identify changes in the nAChR-associated proteasome caused by extended nicotine consumption/exposure. They examine these changes in mice subjected to nicotine, and in humans judged to have been smokers based on cotinine content in the postmortem tissue. Large numbers of components are found to be associated with nAChRs and, strikingly, many are altered by nicotine exposure. A substantial number of the affected components are common to mice and humans.

These are important findings both in terms of basic science and from a biomedical perspective, given the impact of smoking on human health. The results and conclusions appear quite solid. Previous work has demonstrated the ability of the antibody to capture the relevant nAChR subtypes for immunoprecipitation. And in the present studies the authors compare the levels of associated components captured by the antibody in mice of different genotype, i.e wild-type, heterozygous, &amp; knockouts for the relevant nAChR gene(s). This provides confidence that the associated component is indeed associated with the receptor, rather than being non-specifically associated with the antibody complex.

The one non-trivial concern is that it apparently was not possible to demonstrate in mice that the nicotine-induced changes in the nAChR-associated components were in fact also genotype-specific, i.e. that the increased amounts resulting from a nicotine history were seen in wild-type but not in knockouts, etc. The explanation offered appears to be that the numbers of animals (or animal pools) analyzed were too small to provide sufficiently small error bars. This is potentially a problem because one wants to be sure that not only are the components associated with the nAChR (and therefore immunoprecipitated by the antibody) but also that the increases seen after nicotine treatment reflect the same connection, rather than being the results of non-specific entrapment by the antibody complex. This may be a bit of a long-shot concern, but the authors may well want to address it more directly in the Discussion.
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